Ballicules.com

Diltiazem

CARDIZEM

What it isNon-dihydropyridine calcium channel blocker; rate control in atrial fibrillation, angina and hypertension.

Why this oneCompared with verapamil, it causes less constipation and myocardial depression while retaining AV-nodal rate control.

What limits itNegative inotrope: avoid in reduced EF. A moderate CYP3A4 inhibitor, which matters with statins and tacrolimus.

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
Chronic stable angina; angina due to coronary artery spasmAdults30 mg QID (before meals and at bedtime)180–360 mg/day divided TID–QID360 mg/day (usual optimum range upper limit)

Titration Increase gradually at 1–2 day intervals until optimum response.

Renal Undefined (no dosing data; titrate with particular caution).

Hepatic Undefined (no dosing data; titrate with particular caution).

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Animal embryo/fetal lethality and skeletal abnormalities; use only if potential benefit justifies risk.

Lactation Undefined.

NO BOXED WARNINGS

Principal riskBradycardia and heart block; a moderate CYP3A4 inhibitor

Cost, est. cash$4–$80/month

Generic entry1992

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger4 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryC

Defining liabilityBradycardia, heart block and hypotension; overdose can cause refractory cardiogenic shock.

Mechanism of action: Diltiazem ballicule

Diltiazem ballicule: receptor binding, kinetics and half-life diagram

Open Diltiazem in the interactive console ↗

Memory aids: mascots and interaction avatars

Diltiazem CARDIZEM mascot mnemonic cartoon
“Dill ties a Cardigan”
Diltiazem CYP3A4 inhibitor avatar
CYP3A4 inhibitor (moderate)

Open Diltiazem in the interactive console ↗